We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




New Option for Treating Double Chin

By HospiMedica International staff writers
Posted on 19 Aug 2015
Print article
Image: Effects of Kybella: Unretouched photos of clinical trial patient (Sex: F, age: 55, BMI unchanged: 21.8 kg/m2) taken before and after 5 treatment sessions (Photo courtesy of Kythera Biopharmaceuticals).
Image: Effects of Kybella: Unretouched photos of clinical trial patient (Sex: F, age: 55, BMI unchanged: 21.8 kg/m2) taken before and after 5 treatment sessions (Photo courtesy of Kythera Biopharmaceuticals).
A novel, nonsurgical treatment that destroys submental fat cells could eliminate the commonly termed “double chin”.

Kybella is a cytolytic drug identical in formulation to naturally produced deoxycholic acid, which helps the body absorb fats. When properly injected into submental fat, it physically destroys the cell membrane. The procedure involves as many as 20–30 injections in a single treatment, with most patients being treated somewhere between two and four times to achieve the desired outcome. The treatments are done no less than one month apart, and the number of treatments depends on the amount of fat and other factors determined during a consultation.

Kybella should not be used outside of the submental area, and it should not be used if there is an infection at the injection site. Caution should also be used in patients who have had prior surgical or aesthetic treatment of the submental area. Kybella can also cause serious side effects, including nerve injury or facial muscle weakness, and trouble swallowing. The most common side effects include swelling, bruising, pain, numbness, redness and areas of hardness in the treatment area. Kybella is a product of Kythera Biopharmaceuticals (Westlake Village, CA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Treatment with Kybella should only be provided by a licensed healthcare professional, and patients should fully understand the risks associated with use of the drug before considering treatment,” said Amy Egan, MD, MPH, deputy director of the Office of Drug Evaluation III at the FDA Center for Drug Evaluation and Research (CDER). “It is important to remember that Kybella is only approved for the treatment of fat occurring below the chin, and it is not known if Kybella is safe or effective for treatment outside of this area.”

“We will likely see a different patient type seeking treatment with Kybella. Those averse to surgery, including more men, will likely be interested in this new nonsurgical treatment for the "double chin,” said Bardia Amirlak, MD, an assistant professor of plastic surgery at University of Texas (UT) Southwestern (Dallas, USA).

Related Links:

Kythera Biopharmaceuticals
UT Southwestern


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Baby Warmer
THERMOCARE Convenience

Print article

Channels

Critical Care

view channel
Image: AI could help physicians detect abnormal heart rhythms earlier (Photo courtesy of 123RF)

AI to Improved Diagnosis of Atrial Fibrillation

Abnormal heart rhythms frequently arise from—and contribute to—structural abnormalities in the heart. Atrial fibrillation is a specific type of abnormal rhythm that may not be consistently present, often... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.